Solid Biosciences (SLDB) said Wednesday it is teaming up with Mayo Clinic to advance an adeno-associated virus gene therapy platform to develop therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies.
The genetic medicine company said it will receive exclusive licenses to the Mayo Clinic's suppression and replacement gene therapy platform and to six cardiac gene therapy programs developed using the platform.
Solid said its AAV capsids and manufacturing capabilities will be used by the programs to suppress and replace genes implicated in potentially life-threatening genetic heart diseases.
Mayo Clinic will have the research and development responsibilities for the gene therapy candidates up to investigational new drug-enabling studies, at which point Solid can choose to continue the development of commercialization of each program.
Shares of Solid Biosciences were more than 6% higher in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。